481630-46-0Relevant articles and documents
Regiocontrolled Direct C?H Arylation of Indoles at the C4 and C5 Positions
Yang, Youqing,Gao, Pan,Zhao, Yue,Shi, Zhuangzhi
, p. 3966 - 3971 (2017/03/27)
An effective and practical strategy has been established for the direct and site-selective arylation of indoles at the C4 and C5 positions with the aid of a readily accessible, cheap, and removable pivaloyl directing group at the C3 position. This transfo
Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: Design, synthesis, and preclinical characterization
Elokdah, Hassan,Abou-Gharbia, Magid,Hennan, James K.,McFarlane, Geraldine,Mugford, Cheryl P.,Krishnamurthy, Girija,Crandall, David L.
, p. 3491 - 3494 (2007/10/03)
Indole oxoacetic acid derivatives were prepared and evaluated for in vitro binding to and inactivation of human plasminogen activator inhibitor-1 (PAI-1). SAR based on biochemical, physiological, and pharmacokinetic attributes led to identification of tip
Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
-
, (2008/06/13)
This invention provides compounds of the formula: wherein: X is a chemical bond, —CH2— or —C(O)—; R1 is alkyl, cycloalkyl, —CH2-cycloalkyl, pyridinyl, —CH2-pyridinyl, phenyl or benzyl; R2 is H, alkyl, cycloalkyl, —CH2-cycloalkyl, or perfluoroalkyl; R3 is H, halo, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, —CH2-cycloalkyl, —NH2, or —NO2; R4 is optionally substituted phenyl, benzyl, benzyloxy, pyridinyl, or —CH2-pyridinyl, or the salt or ester forms thereof, as well as methods for using the compounds as inhibitors of plasminogen activator inhibitor-1 (PAI-1) and as therapeutic compositions for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.
